PUMA BIOTECHNOLOGY, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
PBYI$8.14-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025 and 2024
(in thousands, except share and per share data)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $29,635 | $69,219 |
| Marketable securities | 67,893 | 31,746 |
| Accounts receivable, net of allowance for credit loss of $0 and $362 | 53,654 | 32,011 |
| Inventory | 5,515 | 8,724 |
| Prepaid expenses, current | 3,642 | 5,867 |
| Restricted cash, current | 2,091 | — |
| Other assets, current | 256 | 91 |
| Total current assets | 162,686 | 147,658 |
| Lease right-of-use assets, net | 5,373 | 4,579 |
| Property and equipment, net | 187 | 515 |
| Intangible assets, net | 41,392 | 51,131 |
| Restricted cash, long-term | — | 2,091 |
| Deferred tax assets | 3,830 | 7,075 |
| Prepaid expenses and other, long-term | 2,834 | 284 |
| Total assets | $216,302 | $213,333 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $5,056 | $5,509 |
| Accrued expenses, current | 50,031 | 36,898 |
| Lease liabilities, current | 1,314 | 5,540 |
| Post-marketing commitment liability | 2,187 | 2,835 |
| Current portion of long-term debt | 22,523 | 45,329 |
| Other liabilities, current | 142 | — |
| Total current liabilities | 81,253 | 96,111 |
| Lease liabilities, long-term | 4,709 | 1,494 |
| Post-marketing commitment liability, long-term | — | 1,763 |
| Long-term debt, net | — | 21,719 |
| Other liabilities, long-term | — | 121 |
| Total liabilities | 85,962 | 121,208 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Common stock - $.0001 par value per share; 100,000,000 shares authorized; 50,408,023 shares issued and outstanding at December 31, 2025 and 49,105,834 issued and outstanding at December 31, 2024 | 5 | 5 |
| Additional paid-in capital | 1,414,074 | 1,407,000 |
| Accumulated other comprehensive income | 36 | 6 |
| Accumulated deficit | (1,283,775) | (1,314,886) |
| Total stockholders’ equity | 130,340 | 92,125 |
| Total liabilities and stockholders’ equity | $216,302 | $213,333 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.